The first is an Opdivo and Yervoy combination for advanced melanoma, the first such immuno-oncology combination therapy approved. The second is for Emplicti, developed with AbbVie for multiple ...

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

Opdivo/Yervoy was cleared for BRAF V600-positive melanoma in 2015, and for all-comer melanoma patients the following year, giving oncologists years of experience with its use and – crucially ...

The randomized study compared combination immunotherapy with nivolumab (Opdivo, Bristol Myers Squibb) and ipilimumab (Yervoy, Bristol Myers Squibb) vs. nivolumab alone in patients with ...

Gavreto is recommended as a first-line treatment for metastatic RET fusion-positive, metastatic non-small cell lung cancer, with potential severe side effects. For patients diagnosed with RET ...

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will be presented this month. Among patients with non-small cell lung cancer ...

These four high-yield blue chip stocks have dependable and growing dividends that provide reliable streams of passive income.

Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500, while capital appreciation has contributed 68%. Therefore, sustainable dividend income and capital ...

After hours: March 21 at 7:56:46 PM EDT Loading Chart for BMY ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further clinical development in a more diverse population.

After hours: 19 March at 19:55:43 GMT-4 Loading Chart for BMY ...